Starpharma Ltd., of Melbourne, Australia, submitted three of the five main modules for its NDA for Vivagel BV for the treatment and prevention of bacterial vaginosis through a rolling submission. The remaining modules are expected to be submitted in the near future. Starpharma is in the process of negotiating global and regional licensing deals for the drug. Read More
HONG KONG – AJ Biologics Sdn. Bhd., of Malaysia, recently broke ground on the first vaccine manufacturing facility in the country and is going after innovation in the vaccine space with the new plant. Read More
HONG KONG – Scientists report having developed new biohybrid micro-robots capable of navigating complex biological environments with high precision, which potentially have biomedical applications including disease monitoring, targeted drug delivery and minimally invasive surgery. Read More
HONG KONG – Hong Kong-based has signed a co-development deal with Beijing Shenogen Pharma Group Ltd. to combine Lee's PD-L1 antibody with Shenogen's lead traditional Chinese medicine-derived small-molecule drug. Read More
HONG KONG – Takeda Pharmaceutical Co. Ltd. has signed a $100 million deal with Portal Instruments Inc. to develop and commercialize a needle-free drug delivery system. Read More
HONG KONG – Samsung Bioepis Co. Ltd. has received approval in both South Korea and Europe for its Herceptin biosimilar. Known as Samfenet in South Korea and as Ontruzant in Europe, it marks the first Herceptin biosimilar to be approved by the European Commission. Read More
